A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

Background: Non-racemic amisulpride (SEP-4199) is an 85:15 ratio of aramisulpride:esamisulpride with a 5-HT7 and D2 receptor binding profile optimized for the treatment of bipolar depression. The aim of this study was to evaluate the efficacy and safety of SEP-4199 for the treatment of bipolar depre...

Full description

Bibliographic Details
Main Authors: Deng, L. (Author), Fava, M. (Author), Hopkins, S.C (Author), Kent, J. (Author), Koblan, K.S (Author), Loebel, A. (Author), Tsai, J. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
Agents, Antidepressive
amisulpride
Amisulpride
bipolar disorder
Bipolar disorder
Bipolar Disorder
controlled study
depression
Depression
Depressive disorder
Diagnostic and Statistical Manual of Mental Disorders
double blind procedure
Double-Blind Method
Enantiomer
human
Humans
randomized controlled trial
Serotonin 7 receptor
treatment outcome
Treatment Outcome
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items